September 18, 2019 / 12:39 PM / a month ago

BRIEF-Novartis Reports Findings Of Five-Year Study In Type 2 Diabetes

Sept 18 (Reuters) - Novartis AG:

* POSITIVE RESULTS FROM NOVARTIS FIVE-YEAR VERIFY STUDY IN TYPE 2 DIABETES DEMONSTRATE LONG-TERM CLINICAL BENEFITS OF EARLY COMBINATION TREATMENT WITH GALVUS® AND METFORMIN

* EARLY COMBINATION THERAPY OF VILDAGLIPTIN (50 MG, TWICE DAILY) AND METFORMIN (INDIVIDUALLY, 1000–2000 MG, DAILY) MET THE PRIMARY ENDPOINT

* COMBINATION TREATMENT STRATEGY ALSO SHOWED A LOWER FREQUENCY OF SECONDARY FAILURE WHEN ALL PATIENTS WERE RECEIVING COMBINATION THERAPY Source text: [reut.rs/2lWKDwW] Further company coverage: (Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below